Clinical Obesity in Adults and Children. Группа авторов. Читать онлайн. Newlib. NEWLIB.NET

Автор: Группа авторов
Издательство: John Wiley & Sons Limited
Серия:
Жанр произведения: Медицина
Год издания: 0
isbn: 9781119695325
Скачать книгу
Lean MEJ, Leslie WS, Barnes AC, et al. Durability of a primary care‐ledweight‐management intervention for remission of type 2 diabetes: 2‐year results of the DiRECT open‐label, cluster‐randomised trial. Lancet Diabetes Endocrinol 2019; 7:344–55.

      79 79. Dobbs R, Sawers C, Thompson F, et al. Overcoming Obesity: An Initial Economic Assessment. A discussion paper by the McKinsey Global Institute, 2014, Available from: http://www.mckinsey.com/industries/healthcare‐systems‐and‐services/our‐insights/how‐the‐world‐could‐better‐fight‐obesity

       Lindsay M. Jaacks1 and Mariachiara Di Cesare2

      1 Global Academy of Agriculture and Food Security, The University of Edinburgh, Roslin, UK

      2 Department of Natural Sciences, Middlesex University, London, UK

      In 2016, a total of 671 million adults (15.7% of women and 11.6% of men) and 124 million children (5.6% of girls and 7.8% of boys) had obesity [1]. If current trends continue unabated, by 2025, the global prevalence of obesity is predicted to exceed 21% in women and 18% in men [2]. At the country level, US‐based simulations previously suggested that the prevalence in adults would plateau at 32% by 2030 [3]. However, the most recent US data (2017–2018) suggest this percentage has already been surpassed with the national prevalence among adults currently 42% [4]. Simulations in Mexico suggest an even higher obesity plateau at 57% of women and 54% of men by 2050 [5], and simulations in Russia suggest that men will far surpass women with a prevalence of obesity of 76% in men compared to 54% in women by 2050 [6]. The call for evidence‐based action against the rising tide of obesity has never been more urgent.

      The global obesity epidemic has been officially recognized by the World Health Organization (WHO) since as early as 1997 [7]. Since then, over the past two decades, governments have repeatedly set targets to address obesity. In the United States, an obesity prevalence target of 30.5% was set as part of the Healthy People 2020 strategy, and was loosened to 36.0% as part of the Healthy People 2030 strategy [8]. On a global scale, in 2013, the United Nations World Health Assembly adopted a global target of halting the rise in obesity by 2025 as part of the targets aimed at reducing premature death from noncommunicable diseases (NCDs). The WHO’s “Comprehensive Implementation Plan for Maternal, Infant and Young Child Nutrition” sets the same target for children [9]. To date, no country is on track to meet targets in adults or children [10]. In every country in the world, over the past four decades, obesity has steadily risen [11]. Only in a handful of population subgroups such as young children is the prevalence starting to plateau, albeit at high levels [11].

      Trends in the global patterning of obesity have led to the development of the obesity transition conceptual framework [12]. Stage 1 is characterized by a higher prevalence of obesity in women than in men, in those with higher socioeconomic status than in those with lower socioeconomic status, and in adults than in children. Many countries in South Asia and sub‐Saharan Africa are presently in this stage. Stage 2 is characterized by a large increase in the prevalence among adults, a smaller increase among children, and a narrowing of the gap between sexes and in socioeconomic differences among women. Many Latin American countries are presently at this stage. Stage 3 is characterized by the “reversal hypothesis” in which the prevalence of obesity among those with lower socioeconomic status surpasses that of those with higher socioeconomic status, and plateaus in prevalence can be observed in women with high socioeconomic status and in children. The United States and most European countries are presently at this stage. A hypothetical Stage 4 would be characterized by declines in the prevalence of obesity, but no country is yet at this stage.

      Anthropometric measures are easy, quick, cheap, reliable, and perform well to identify those at high risk of obesity‐related morbidities. Anthropometric measures are therefore more commonly used in clinical and monitoring settings as compared to more accurate, but also more expensive, measures such as total body fat from underwater weighing (densitometry) and dual‐energy X‐ray absorptiometry (DXA), or fat distribution from computed tomography (CT) and magnetic resonance imaging (MRI).

      Body mass index (BMI) is the most often used anthropometric measure in children and adults because it is quick, easy, cheap, and reliable, especially if personnel are trained. BMI is calculated as body weight (kg) divided by the square of body height (m). Body weight should be measured without shoes or heavy clothing and with empty pockets. Reliable and accurate electronic scales are increasingly affordable and widely available. Height is measured without shoes with the back square against a wall tape and with the eyes looking straight ahead.


e-mail: [email protected]

Country Name (organization) Geographic coverage Measured or self‐reported Years Age
United States NHANES (CDC) National Measured 1971–1974 1976–1980 1988–1994 Continuously since 1999–2000 (e.g. 2001–2002, 2003–2004, …, 2019–2020) All
BRFSS (CDC) National Self‐reported Annual since 1985 ≥18 years
Global NCD‐RisC Global Modeled estimates using measured BMI 1975–2016 ≥5 years